Relief Therapeutics Holding AG: Shareholders Approve All Proposals at Annual General Meeting

In a decisive move, Relief Therapeutics Holding AG, a commercial-stage biopharmaceutical company specializing in rare metabolic disorders, rare pulmonary diseases, and rare connective tissue disorders, has successfully concluded its Annual General Meeting (AGM) with shareholders approving all proposals by a large majority. The meeting, held in Geneva, Switzerland, underscores the company’s strong governance and strategic direction as it continues to operate globally with its main base in Switzerland.

Relief Therapeutics, listed on the SIX Swiss Exchange, has been navigating a challenging financial landscape, as evidenced by its recent stock performance. The company’s close price on June 10, 2025, stood at 2.18 CHF, a significant drop from its 52-week high of 7.6 CHF on November 11, 2024. The 52-week low was recorded at 1.055 CHF on August 26, 2024. Despite these fluctuations, the company maintains a market capitalization of 31,170,000 CHF, reflecting investor confidence in its long-term potential.

The approval of all proposals at the AGM is a testament to the company’s robust strategic initiatives and its commitment to advancing its pipeline of therapies. Relief Therapeutics continues to focus on its core mission of developing and commercializing innovative treatments for rare diseases, a sector that remains underserved and ripe for breakthroughs.

In the broader market context, the Swiss Performance Index (SPI) has experienced volatility, with recent sessions showing mixed results. On June 12, 2025, the SPI opened with a slight decline, reflecting a cautious sentiment among investors. However, the market’s overall resilience suggests a potential for recovery, which could bode well for companies like Relief Therapeutics that are positioned to capitalize on emerging opportunities in the healthcare sector.

As Relief Therapeutics moves forward, its leadership remains focused on leveraging its expertise in rare diseases to drive growth and deliver value to shareholders. The company’s strategic initiatives, coupled with a supportive shareholder base, position it well to navigate the complexities of the pharmaceutical industry and achieve its long-term objectives.

For more information on Relief Therapeutics and its ongoing developments, stakeholders are encouraged to visit the company’s website at www.relieftherapeutics.com .